Natural Plant Extract Powder Huperzine a CAS 120786-18-7 1%~99% Purity

• Customization: Available
• Certification: ISO, Halal
• Assay Method: HPLC-MS, HPLC
• Model NO.: NY015
• Application Form: Injection, Capsule, Softgels, Tinctures, Liquids, Drops
• Application: Health Care Products, Medicine
• State: Powder
• Extract Source: Lycopodium Serratum Thunb
• Transport Package: 25kg/Drum
• Specification: Lycopodium serratum Thunb
• Trademark: Nutrayours/ OEM
• Origin: China
• HS Code: 1302199099
• Production Capacity: 3000kg/Year

Product Description

Basic Info.

        

• 100% NATURAL PRODUCT: No artificial colors or flavors
• Verified herb identity, confirmed highest quality of raw materials and the extract
• Best natural sources of herbs and raw materials: Every vendor is carefully picked to meet our high standards
• hird-party lab tested, All natura Huperzia serrata Extract/Huperzine-A 

  Model NO.	HW-HUP-002
  Product Name	Huperzine a
  Function	Health Care/Medicine
  Specification	99% Huperzine A
  Origin	China
  Test Method	HPLC

   Huperzine A, a reversible inhibitor of acetylcholinesterase, has the characteristics of high selectivity, low toxicity and long efficacy, and is an ideal candidate drug for the treatment of Alzheimer's disease in the world. It can be used formyasthenia gravis, senile memory decline and Alzheimer's disease,adolescent learning disabilities and memory enhancement
  The effect of huperzine A wassimilar to that of Neostigmine, but the duration of improving muscle strength was longer than that of neostigmine. The memoryenhancing effect was stronger than physostigmine, but the toxicity was lower. The results of animal experiments showed that huperzine A can promote the learning process of light-dark resolution in rats and reverse the memory impairment caused by scopolamine.Clinical studies have shown that huperzine A improves memory, cognition and behavior in patients withAlzheimer's disease, with significant differences compared to placebo.
 

About us

* The statements in this section have not been evaluated by the FDA or EFSA.

References

1.Molecules. 2021 Oct 29;26(21):6531. doi: 10.3390/molecules26216531.PMID: 34770940

2.Villegas C, Perez R, Petiz LL, Glaser T, Ulrich H, Paz C.IUBMB Life. 2022 Aug;74(8):763-779. doi: 10.1002/iub.2613. Epub 2022 Apr 5.PMID: 35384262
3.Li X, Li W, Tian P, Tan T.Biotechnol Adv. 2022 Nov;60:108026. doi: 10.1016/j.biotechadv.2022.108026. Epub 2022 Jul 30.
PMID: 35914626 

4.Sang X, Yang M, Su J.Crit Rev Microbiol. 2020 Nov;46(6):654-664. doi: 10.1080/1040841X.2020.1819771. Epub 2020 Sep 24.
PMID: 32970952